

**RCW 69.50.204 Schedule I.** Unless specifically excepted by state or federal law or regulation or more specifically included in another schedule, the following controlled substances are listed in Schedule I:

(a) [(1)] Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation:

(1) [(a)] Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide);

(2) [(b)] Acetylmethadol;

(3) [(c)] Allylprodine;

(4) [(d)] Alphacetylmethadol, except levo-alpha-acetylmethadol, also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM;

(5) [(e)] Alphameprodine;

(6) [(f)] Alphamethadol;

(7) [(g)] Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide); (1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine);

(8) [(h)] Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

(9) [(i)] Benzethidine;

(10) [(j)] Betacetylmethadol;

(11) [(k)] Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide);

(12) [(l)] Beta-hydroxy-3-methylfentanyl, some trade or other names: N-[1-(2-hydrox-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide;

(13) [(m)] Betameprodine;

(14) [(n)] Betamethadol;

(15) [(o)] Betaprodine;

(16) [(p)] Clonitazene;

(17) [(q)] Dextromoramide;

(18) [(r)] Diampromide;

(19) [(s)] Diethylthiambutene;

(20) [(t)] Difenoquin;

(21) [(u)] Dimenoxadol;

(22) [(v)] Dimepheptanol;

(23) [(w)] Dimethylthiambutene;

(24) [(x)] Dioxaphetyl butyrate;

(25) [(y)] Dipipanone;

(26) [(z)] Ethylmethylthiambutene;

(27) [(aa)] Etonitazene;

(28) [(bb)] Etoxadine;

(29) [(cc)] Furethidine;

(30) [(dd)] Hydroxypethidine;

(31) [(ee)] Ketobemidone;

(32) [(ff)] Levomoramide;

(33) [(gg)] Levophenacetylmorphan;

(34) [(hh)] 3-Methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylprop anamide);

(35) [(ii)] 3-Methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

(36) [(jj)] Morpheridine;

(37) [(kk)] MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);

(38) [(ll)] Noracetylmethadol;

- (39) [(mm)] Norlevorphanol;
- (40) [(nn)] Normethadone;
- (41) [(oo)] Norpipanone;
- (42) [(pp)] Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl] propanamide);
- (43) [(qq)] PEPAP(1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
- (44) [(rr)] Phenadoxone;
- (45) [(ss)] Phenampromide;
- (46) [(tt)] Phenomorphan;
- (47) [(uu)] Phenoperidine;
- (48) [(vv)] Piritramide;
- (49) [(ww)] Proheptazine;
- (50) [(xx)] Properidine;
- (51) [(yy)] Propiram;
- (52) [(zz)] Racemoramide;
- (53) [(aaa)] Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide);
- (54) [(bbb)] Tilidine;
- (55) [(ccc)] Trimeperidine.

(b) [(2)] Opium derivatives. Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, including their salts, isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) [(a)] Acetorphine;
- (2) [(b)] Acetyldihydrocodeine;
- (3) [(c)] Benzylmorphine;
- (4) [(d)] Codeine methylbromide;
- (5) [(e)] Codeine-N-Oxide;
- (6) [(f)] Cyprenorphine;
- (7) [(g)] Desomorphine;
- (8) [(h)] Dihydromorphine;
- (9) [(i)] Drotebanol;
- (10) [(j)] Etorphine, except hydrochloride salt;
- (11) [(k)] Heroin;
- (12) [(l)] Hydromorphanol;
- (13) [(m)] Methyldesorphine;
- (14) [(n)] Methyldihydromorphine;
- (15) [(o)] Morphine methylbromide;
- (16) [(p)] Morphine methylsulfonate;
- (17) [(q)] Morphine-N-Oxide;
- (18) [(r)] Myrophine;
- (19) [(s)] Nicocodeine;
- (20) [(t)] Nicomorphine;
- (21) [(u)] Normorphine;
- (22) [(v)] Pholcodine;
- (23) [(w)] Thebacon.

(c) [(3)] Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation. For the purposes of this subsection only, the term "isomer" includes the optical, position, and geometric isomers:

- (1) [(a)] Alpha-ethyltryptamine: Some trade or other names: Etryptamine; monase; a-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; a-ET; and AET;
- (2) [(b)] 4-bromo-2,5-dimethoxy-amphetamine: Some trade or other names: 4-bromo-2,5-dimethoxy-a-methylphenethylamine; 4-bromo-2,5-DMA;
- (3) [(c)] 4-bromo-2,5-dimethoxyphenethylamine: Some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, nexus;
- (4) [(d)] 2,5-dimethoxyamphetamine: Some trade or other names: 2,5-dimethoxy-a-methylphenethylamine; 2,5-DMA;
- (5) [(e)] 2,5-dimethoxy-4-ethylamphetamine (DOET);
- (6) [(f)] 2,5-dimethoxy-4-(n)-propylthiophenethylamine: Other name: 2C-T-7;
- (7) [(g)] 4-methoxyamphetamine: Some trade or other names: 4-methoxy-a-methylphenethylamine; paramethoxyamphetamine, PMA;
- (8) [(h)] 5-methoxy-3,4-methylenedioxy-amphetamine;
- (9) [(i)] 4-methyl-2,5-dimethoxy-amphetamine: Some trade and other names: 4-methyl-2,5-dimethoxy-a-methylphenethylamine; "DOM"; and "STP";
- (10) [(j)] 3,4-methylenedioxy amphetamine;
- (11) [(k)] 3,4-methylenedioxymethamphetamine (MDMA);
- (12) [(l)] 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA;
- (13) [(m)] N-hydroxy-3,4-methylenedioxyamphetamine also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, N-hydroxy MDA;
- (14) [(n)] 3,4,5-trimethoxy amphetamine;
- (15) [(o)] Alpha-methyltryptamine: Other name: AMT;
- (16) [(p)] Bufotenine: Some trade or other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine;
- (17) [(q)] Cannabis;
- (18) [(r)] Diethyltryptamine: Some trade or other names: N,N-Diethyltryptamine; DET;
- (19) [(s)] Dimethyltryptamine: Some trade or other names: DMT;
- (20) [(t)] 5-methoxy-N,N-diisopropyltryptamine: Other name: 5-MeO-DIPT;
- (21) [(u)] Ibogaine: Some trade or other names: 7-Ethyl-6,6 beta,7,8,9,10,12,13,-octahydro-2-methoxy-6,9-methano-5H-pyndo (1',2' 1,2) azepino (5,4-b) indole; Tabernanthe iboga;
- (22) [(v)] Lysergic acid diethylamide;
- (23) [(w)] Mescaline;
- (24) [(x)] Parahexyl-7374: Some trade or other names: 3-Hexyl-1-hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo[b,d]pyran; synhexyl;
- (25) [(y)] Peyote, meaning all parts of the plant presently classified botanically as Lophophora Williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds, or extracts; (interprets 21 U.S.C. Sec. 812 (c), Schedule I (c)(12));
- (26) [(z)] N-ethyl-3-piperidyl benzilate;
- (27) [(aa)] N-methyl-3-piperidyl benzilate;
- (28) [(bb)] Psilocybin;
- (29) [(cc)] Psilocyn;

(30) [(dd)](i) Tetrahydrocannabinols, meaning tetrahydrocannabinols naturally contained in a plant of the genera Cannabis, as well as synthetic equivalents of the substances contained in the plant, or in the resinous extractives of the genera Cannabis, and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity such as the following:

(A) 1 - cis - or trans tetrahydrocannabinol, and their optical isomers, excluding tetrahydrocannabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United States Food and Drug Administration;

(B) 6 - cis - or trans tetrahydrocannabinol, and their optical isomers;

(C) 3,4 - cis - or trans tetrahydrocannabinol, and its optical isomers; or

(D) That is chemically synthesized and either:

(I) Has been demonstrated to have binding activity at one or more cannabinoid receptors; or

(II) Is a chemical analog or isomer of a compound that has been demonstrated to have binding activity at one or more cannabinoid receptors;

(Since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered.)

(ii) Hemp and industrial hemp, as defined in RCW 15.140.020, are excepted from the categories of controlled substances identified under this section;

(31) [(ee)] Ethylamine analog of phencyclidine: Some trade or other names: N-ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl) ethylamine; N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; PCE;

(32) [(ff)] Pyrrolidine analog of phencyclidine: Some trade or other names: 1-(1-phenylcyclohexyl)pyrrolidine; PCPy; PHP;

(33) [(gg)] Thiophene analog of phencyclidine: Some trade or other names: 1-(1-[2-thienyl]-cyclohexyl)-piperidine; 2-thienyl analog of phencyclidine; TCPy; TCP;

(34) [(hh)] 1-[1-(2-thienyl)cyclohexyl]pyrrolidine: A trade or other name is TCPy.

(d) [(4)] Depressants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation.

(1) [(a)] Gamma-hydroxybutyric acid: Some other names include GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate;

(2) [(b)] Mecloqualone;

(3) [(c)] Methaqualone.

(e) [(5)] Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1) [(a)] Aminorex: Some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4, 5-dihydro-5-phenyl-2-oxazolamine;

(2) [(b)] N-Benzylpiperazine: Some other names:  
BZP, 1-benzylpiperazine;

(3) [(c)] Cathinone, also known as 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone, 2-aminopropiophenone and norephedrone;

(4) [(d)] Fenethylamine;

(5) [(e)] Methcathinone: Some other names: 2-(methylamino)-propiofenone; alpha-(methylamino)propiofenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-methylaminopropiofenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of optical isomers;

(6) [(f)] (+/-)cis-4-methylaminorex ((+/-)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);

(7) [(g)] N-ethylamphetamine;

(8) [(h)] N,N-dimethylamphetamine: Some trade or other names: N,N-alpha-trimethyl-benzeneethanamine; N,N-alpha-trimethylphenoethylene.

The controlled substances in this section may be added, rescheduled, or deleted as provided for in RCW 69.50.201. [2022 c 16 s 53; 2019 c 158 s 13; 2015 2nd sp.s. c 4 s 1203; 2010 c 177 s 2; 1993 c 187 s 4; 1986 c 124 s 3; 1980 c 138 s 1; 1971 ex.s. c 308 s 69.50.204.]

**Intent—Finding—2022 c 16:** See note following RCW 69.50.101.

**Effective date—2019 c 158:** See RCW 15.140.900.

**Findings—Intent—Effective dates—2015 2nd sp.s. c 4:** See notes following RCW 69.50.334.

*Pharmacy quality assurance commission may change schedules of controlled substances: RCW 69.50.201.*